Brian Druker
Net worth: 3 M $ as of 2026-05-30
Net worth: 3 M $ as of 2026-05-30
Brian J.
Druker is the founder of MolecularMD Corp., founded in 2005, and Blueprint Medicines Corp., founded in 2008.
Dr. Druker currently serves as an Independent Director at Amgen, Inc. since 2018, Director & Associate Dean at Oregon Health & Science University since 2010, and Director at The Burroughs Wellcome Fund.
Formerly, Dr. Druker was Chief Executive Officer & Director at OHSU Knight Cancer Institute from 2007 to 2024 and Independent Director at Vincerx Pharma, Inc. from 2020 to 2025.
Dr. Druker completed undergraduate and doctorate degrees at the University of California San Diego.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-05-18 | 8,391 ( 0% ) | 3 M $ | 2026-05-30 | |
VINCERX PHARMA INC 0.06% | 2025-03-20 | 3,073 ( 0.06% ) | 40 $ | 2026-05-30 |
| Companies | Position | Start |
|---|---|---|
| AMGEN INC. | Director/Board Member | 2018-05-22 |
Oregon Health & Science University
Oregon Health & Science University Other Consumer ServicesConsumer Services Functions as a College/University | Director/Board Member | 2007-06-30 |
The Burroughs Wellcome Fund
The Burroughs Wellcome Fund Investment Trusts/Mutual FundsMiscellaneous Operates an independent private foundation dedicated to advancing the medical sciences by supporting research and other scientific and educational activities | Director/Board Member | - |
| Companies | Position | End |
|---|---|---|
| VINCERX PHARMA, INC. | Director/Board Member | 2025-06-29 |
OHSU Knight Cancer Institute
OHSU Knight Cancer Institute Medical/Nursing ServicesHealth Services Part of Oregon Health & Science University, OHSU Knight Cancer Institute is a comprehensive cancer center specializing in a broad spectrum of cancers, including breast, colon, leukemia, liver, lung, lymphoma, pancreatic, prostate, and pediatric cancers. The company is based in OR. The institute offers advanced, personalized treatment options such as immunotherapy, chemotherapy, radiation, surgery, targeted therapies, CAR T-cell therapy, and tumor-infiltrating lymphocyte (TIL) therapy. It operates multiple locations across Portland and surrounding areas, including community clinics, the OHSU Breast Center, and OHSU Doernbecher Children’s Hospital, emphasizing accessible, team-based, and patient-centered care. The institute provides patient and family support services, genetic counseling, cancer screening programs, and navigation assistance. Research and innovation are central to its mission, with numerous research projects and clinical trials underway annually, focusing on precision cancer medicine, early detection, and translational research. It hosts specialized research resources and collaborates with national and international partners. The institute also offers training programs for healthcare professionals and engages in community outreach through grants and public programs. | Chief Executive Officer | 2024-12-07 |
MolecularMD Corp.
MolecularMD Corp. Medical/Nursing ServicesHealth Services Develops and commercializes molecular diagnostics for oncology applications | Founder | - |
| BLUEPRINT MEDICINES CORPORATION | Founder | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 8 |
|---|---|
Amgen, Inc.
Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
Oregon Health & Science University
Oregon Health & Science University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California San Diego
University of California San Diego Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Burroughs Wellcome Fund
The Burroughs Wellcome Fund Investment Trusts/Mutual FundsMiscellaneous Operates an independent private foundation dedicated to advancing the medical sciences by supporting research and other scientific and educational activities | Miscellaneous |
MolecularMD Corp.
MolecularMD Corp. Medical/Nursing ServicesHealth Services Develops and commercializes molecular diagnostics for oncology applications | Health Services |
Blueprint Medicines Corp.
Blueprint Medicines Corp. BiotechnologyHealth Technology Develops cancer therapies that harness the growing understanding of the molecular blueprint of cancer | Health Technology |
Vincerx Pharma, Inc.
Vincerx Pharma, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops therapies to address cancer | Health Technology |
OHSU Knight Cancer Institute
OHSU Knight Cancer Institute Medical/Nursing ServicesHealth Services Part of Oregon Health & Science University, OHSU Knight Cancer Institute is a comprehensive cancer center specializing in a broad spectrum of cancers, including breast, colon, leukemia, liver, lung, lymphoma, pancreatic, prostate, and pediatric cancers. The company is based in OR. The institute offers advanced, personalized treatment options such as immunotherapy, chemotherapy, radiation, surgery, targeted therapies, CAR T-cell therapy, and tumor-infiltrating lymphocyte (TIL) therapy. It operates multiple locations across Portland and surrounding areas, including community clinics, the OHSU Breast Center, and OHSU Doernbecher Children’s Hospital, emphasizing accessible, team-based, and patient-centered care. The institute provides patient and family support services, genetic counseling, cancer screening programs, and navigation assistance. Research and innovation are central to its mission, with numerous research projects and clinical trials underway annually, focusing on precision cancer medicine, early detection, and translational research. It hosts specialized research resources and collaborates with national and international partners. The institute also offers training programs for healthcare professionals and engages in community outreach through grants and public programs. | Health Services |
Select your edition
All financial news and data tailored to specific country editions